Switch theme
Sign up to access all valuation multiples
Lipocine Inc is a clinical-stage biopharmaceutical company, that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP’RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.
1997
16
LTM Revenue $6.9M
Last FY EBITDA -$1.1M
-$1.6M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Lipocine has a last 12-month revenue (LTM) of $6.9M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Lipocine achieved revenue of $11.2M and an EBITDA of -$1.1M.
Lipocine expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Lipocine valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $6.9M | XXX | $11.2M | XXX | XXX | XXX |
| Gross Profit | $6.9M | XXX | $3.8M | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | 34% | XXX | XXX | XXX |
| EBITDA | n/a | XXX | -$1.1M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -10% | XXX | XXX | XXX |
| EBIT | -$4.9M | XXX | -$1.2M | XXX | XXX | XXX |
| EBIT Margin | -70% | XXX | -10% | XXX | XXX | XXX |
| Net Profit | -$4.0M | XXX | $8K | XXX | XXX | XXX |
| Net Margin | -57% | XXX | 0% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Lipocine's stock price is $3.
Lipocine has current market cap of $18.1M, and EV of -$1.6M.
See Lipocine trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$1.6M | $18.1M | XXX | XXX | XXX | XXX | $-0.73 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Lipocine has market cap of $18.1M and EV of -$1.6M.
Lipocine's trades at -0.1x EV/Revenue multiple, and 1.5x EV/EBITDA.
Equity research analysts estimate Lipocine's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Lipocine has a P/E ratio of -4.6x.
See valuation multiples for Lipocine and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $18.1M | XXX | $18.1M | XXX | XXX | XXX |
| EV (current) | -$1.6M | XXX | -$1.6M | XXX | XXX | XXX |
| EV/Revenue | -0.2x | XXX | -0.1x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | 1.5x | XXX | XXX | XXX |
| EV/EBIT | 0.3x | XXX | 1.4x | XXX | XXX | XXX |
| EV/Gross Profit | -0.2x | XXX | n/a | XXX | XXX | XXX |
| P/E | -4.6x | XXX | 2165.3x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 1.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialLipocine's last 12 month revenue growth is -90%
Lipocine's revenue per employee in the last FY averaged $0.7M, while opex per employee averaged $0.3M for the same period.
Lipocine's rule of 40 is 483% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Lipocine's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Lipocine and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -90% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -10% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | 483% | XXX | -100% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.7M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 45% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Lipocine acquired XXX companies to date.
Last acquisition by Lipocine was XXXXXXXX, XXXXX XXXXX XXXXXX . Lipocine acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Lipocine founded? | Lipocine was founded in 1997. |
| Where is Lipocine headquartered? | Lipocine is headquartered in United States of America. |
| How many employees does Lipocine have? | As of today, Lipocine has 16 employees. |
| Who is the CEO of Lipocine? | Lipocine's CEO is Dr. Mahesh V. Patel, PhD. |
| Is Lipocine publicy listed? | Yes, Lipocine is a public company listed on NAS. |
| What is the stock symbol of Lipocine? | Lipocine trades under LPCN ticker. |
| When did Lipocine go public? | Lipocine went public in 2012. |
| Who are competitors of Lipocine? | Similar companies to Lipocine include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Lipocine? | Lipocine's current market cap is $18.1M |
| What is the current revenue of Lipocine? | Lipocine's last 12 months revenue is $6.9M. |
| What is the current revenue growth of Lipocine? | Lipocine revenue growth (NTM/LTM) is -90%. |
| What is the current EV/Revenue multiple of Lipocine? | Current revenue multiple of Lipocine is -0.2x. |
| Is Lipocine profitable? | Yes, Lipocine is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
